Multiple Myeloma

Stand Up To Cancer Catalyst® Launches 10 Clinical Trial Projects Combining Cancer Treatments from Nine Different Pharmaceutical Companies to Explore Innovative Approaches and Find New Indications for Blockbuster Drugs to Improve Patient Outcomes

(AACR) Oct 12, 2017 - Stand Up To Cancer (SU2C) has awarded 10 SU2C Catalyst® clinical trial projects in which researchers from more than 30 institutions collaborate across academic and corporate borders on clinical trials – with correlated translational research which will deepen our understanding of why treatments are effective – across a variety of cancers, in a program supported by industry.

read press release

Karyopharm Bags A $193M Asian Deal For Selinexor And Followup Drug, Shares Jump

(Endpoints News) Oct 12, 2017 - Karyopharm Therapeutics has inked a regional Asian deal for its late-stage cancer therapy selinexor and a follow-up compound it has in the pipeline.

read article

New Myeloma Clinical Trial Launches With Aim To Transform Treatment From One-Size-Fits-All Approach

(ICR [UK]) Oct 10, 2017 - People with newly diagnosed high risk myeloma will be treated based on the results of genetic testing as part of a new UK-first clinical trial.

read article

Inova Schar Cancer Institute Recruiting Patients For ASCO's Groundbreaking TAPUR Clinical Trial

(Inova) Oct 5, 2017 - Inova Schar Cancer Institute announced today it is recruiting patients for the American Society of Clinical Oncology's (ASCO) first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

read press release

Cancers Associated with Overweight and Obesity Make up 40 percent of Cancers Diagnosed in the United States

(CDC) Oct 3, 2017 - Overweight and obesity are associated with increased risk of 13 types of cancer. These cancers account for about 40 percent of all cancers diagnosed in the United States in 2014, according to the latest Vital Signs report by the Centers for Disease Control and Prevention (CDC).

read press release

bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

(bluebird bio) Sept 28, 2017 - bluebird bio, Inc. announced the treatment of the first patient with relapsed/refractory multiple myeloma in a Phase 1 study of bb21217. bb21217 is an investigational chimeric antigen receptor T cell (CAR T) therapy targeting B cell maturation antigen (BCMA).

read corporate press release

Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma

(Poseida) Sept 26, 2017 - Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, is now enrolling patients in its Phase 1 study of P-BCMA-101, the company’s lead investigational chimeric antigen receptor T cell (CAR-T) immunotherapy for the treatment of multiple myeloma.

read corporate press release

Nation’s Experts in Hematologic Malignancies to Discuss Latest Treatment Advances and Examine Patient Cases during NCCN 12th Annual Congress

(NCCN) Sept 22, 2017 - NCCN 12th Annual Congress: Hematologic Malignancies™ will be held October 6 – 7, 2017 in San Francisco, California, and features a new Nursing Forum.

read press release

NCCN Guidelines to Include Categories of Preference

(NCCN) Sept 15, 2017 - NCCN categories of preference will provide guidance on which recommendations within the NCCN Guidelines are optimal, while providing a range of recommendations to accommodate a variety of clinical circumstances.

read press release

Autolus Announces First-Dose Cohort Completed in APRIL Study of AUTO2: A Phase I/II Study in Patients with Multiple Myeloma

(Autolus) Sept 18, 2017 - Autolus Limited, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, today announced completion of the first-dose cohort of its phase I/II study of its novel, dual-targeted Chimeric Antigen Receptor (CAR) in patients with relapsed/refractory multiple myeloma.

read corporate press release

FDA Adds Two Roche Studies To Its Growing List Of Partial Clinical Holds In Wake Of Keytruda Deaths

(Endpoints News) Sept 15, 2017 - Alarmed that an imbalance in deaths among patients taking a combination of Keytruda with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint combos, the FDA has added two Tecentriq studies to its growing list of clinical trials placed on partial hold.

read article

Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center

(Yahoo! Finance [UK]) Sept 18, 2017 - Karus Therapeutics, a leader in the development of innovative, orally-active medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed in a Phase I study for its lead candidate, KA2237.

read article

Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study

(Oncolytics Biotech) Sept 14, 2017 - Oncolytics Biotech® Inc. today announced that the first patient has been treated in the Phase 1b trial MUK eleven, studying REOLYSIN in combination with Celgene Corporation's immunomodulatory drugs (IMiDs), Revlimid® or Imnovid® as a rescue treatment in relapsing myeloma patients.

read corporate press release

Bluebird Bio Announces First Patient Treated In Expansion Cohort Of CRB-401, Phase 1 Study Of Anti-BCMA CAR T Therapy BB2121

(Yahoo! Finance) Sept 13, 2017 - bluebird bio, Inc. today announced that the expansion cohort of the CRB-401 Phase 1 study of bb2121, an anti-BCMA CAR T therapy, has been initiated.

read article

DNA Sequencing Could Open Up New Drug Indications for Patients with Rare Cancers

(ESMO 2017 Congress) Sept 8, 2017 - Thanks to DNA sequencing, patients with rare cancers for which no standard treatment is available could receive existing therapies that work in patients treated for different cancers, but who carry the same genetic mutations.

read press release

GSK Bets On Pioneering Cancer Therapy With Adaptimmune Deal

(Reuters) Sept 7, 2017 - GlaxoSmithKline said it has licensed the rights to Adaptimmune’s pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas its has prioritized for research and development.

read article

Safety Fears Spur FDA to Pause Checkpoint Combo Studies By Bristol-Myers, Celgene

(Endpoints News) Sept 7, 2017 - Two months after the FDA ordered Merck to slam the brakes on three Keytruda combo studies targeting multiple myeloma, alarmed regulators have followed up by posting a stop sign on enrolling any new patients in Bristol-Myers Squibb’s three rival studies concentrating on the same disease with the same combination approaches.

read article

Bristol-Myers Squibb Provides an Update on Three Opdivo-based Combination Clinical Studies in Multiple Myeloma

(BMS) Sept 6, 2017 - The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on CA209602 (CheckMate-602), CA209039 (CheckMate-039) and CA204142, three clinical trials investigating Opdivo (nivolumab)-based combinations in patients with relapsed or refractory multiple myeloma.

read corporate press release

Celgene Provides Update on the Fusion™ Clinical Program

(StreetInsider) Sept 7, 2017 - Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a full clinical hold on one trial in the Celgene FUSION™ program.

read article

The Cancer Patient Taking On High Drug Prices

(The Atlantic) Sept 6, 2017 - It takes $440,000 of medications a year to keep David Mitchell alive. Now he’s founded a nonprofit to make drugs more affordable.

read article
Next Page